Open access
Jul 2026
Lycorine ameliorates diabetic nephropathy by targeting RAGE and inhibiting the HMGB1/RAGE/NF-κB signaling axis
Lycorine is identified as a potential RAGE-targeting therapeutic candidate for inflammation-driven diabetic kidney injury and ameliorates diabetic nephropathy without affecting blood glucose levels by directly targeting RAGE and suppressing the HMGB1/RAGE/NF-κB signaling axis.
Zheng Xu, Xuejin Jin, Miao Yuan et al.
· Chinese Medicine · 1 citation